Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology

Neuroscience

• 5-HT Receptor 50%
• Adrenergic Receptor 50%
• AMPA 50%
• Antipsychotic 50%
• Autoreceptor 50%
• Cannabinoid 50%
• Cholinergic Receptor 50%
• Dopamine Agonist 50%
• Dopamine Receptor D2 50%
• Dopamine Release 50%
• Dysphoria 50%
• Histamine Receptor 50%
• In Vitro 50%
• Molecular Imaging 50%
• Negative Syndrome 100%
• Neuroscience 50%
• Nicotinic Agonist 50%
• Phosphodiesterase Inhibitor 50%
• Positive Syndrome 50%
• Receptor 50%
• Receptor Agonists 50%
• Striatum 50%
• Trace Amine 50%
• Treatment of Schizophrenia 50%

Medicine and Dentistry

• Adrenergic Receptor 20%
• AMPA 20%
• Antipsychotic Drug 20%
• Autoreceptor 20%
• Cannabinoid 20%
• Cholinergic Receptor 20%
• Clinical Imaging 20%
• Diseases 20%
• Dopamine Agonist 20%
• Dopamine Metabolism 40%
• Dopamine Receptor D2 20%
• Dopamine Release 40%
• Dorsal Region 20%
• Dysphoria 20%
• Histamine Receptor 20%
• In Vitro 20%
• Molecular Imaging 20%
• Negative Syndrome 40%
• Nicotinic Agonist 20%
• Pathophysiology 100%
• Phosphodiesterase Inhibitor 20%
• Positive Syndrome 20%
• Receptor 40%
• Receptor Blocking 20%
• Serotonin Receptor 20%
• Side Effect 100%
• Striatum 20%
• Therapeutic Window 20%
• Trace Amine 20%
• Treatment of Schizophrenia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adrenergic Receptor 20%
• Alpha Amino 3 Hydroxy 5 Methyl 4 Isoxazolepropionic Acid 20%
• Antipsychotic Drug 20%
• Autoreceptor 20%
• Cannabinoid 20%
• Cholinergic Receptor 20%
• Diseases 20%
• Dopamine Receptor D2 20%
• Dopamine Receptor Stimulating Agent 20%
• Dysphoria 20%
• Histamine Receptor 20%
• Negative Syndrome 40%
• Nicotinic Agent 20%
• Pathophysiology 100%
• Phosphodiesterase Inhibitor 20%
• Positive Syndrome 20%
• Receptor 20%
• Receptor Agonist 20%
• Serotonin Receptor 20%
• Side Effect 100%
• Therapeutic Window 20%